FAQ/Help |
Calendar |
Search |
Today's Posts |
11-12-2016, 11:05 PM | #1 | ||
|
|||
Member
|
Progress in reducing alpha synuclein but another year has gone by!
Prothena Reports Results from Phase 1b Study of PRX 2 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson's Disease (NASDAQ:PRTA) |
||
Reply With Quote |
11-13-2016, 01:12 PM | #2 | ||
|
|||
Member
|
Zanpar, assuming everything checks out in phase 2 and 3, how many years would it take before it might be available? Would neurons be restored, or is this drug only going to halt or slow down PD progression? Is this drug our best hope in your opinion?
|
||
Reply With Quote |
11-13-2016, 07:45 PM | #3 | ||
|
|||
Member
|
Quote:
At 5 Years, Nilotinib Offers Benefit Over Imatinib in CML | Cancer Network Last edited by zanpar321; 11-13-2016 at 10:27 PM. |
||
Reply With Quote |
11-14-2016, 08:52 PM | #4 | ||
|
|||
Member
|
Quote:
Parkinson's Disease | Podcast: Parkinson's Common Denominator -- A Sticky Protein |
||
Reply With Quote |
11-23-2016, 02:26 PM | #5 | ||
|
|||
Member
|
An experimental Alzheimer’s drug that had previously appeared to show promise in slowing the deterioration of thinking and memory has failed in a large Eli Lilly clinical trial, dealing a significant disappointment to patients hoping for a treatment that would alleviate their symptoms.
The failure of the drug, solanezumab, underscores the difficulty of treating patients who have reached the point of showing even mild dementia, and supports the idea that by that time the damage in their brains may already be too extensive. And because the drug attacked the amyloid plaques that are the hallmark of Alzheimer’s, the trial results renew questions about a leading theory of the disease, which contends that it is largely caused by amyloid buildup. http://www.nytimes.com/2016/11/23/he...rial.html?_r=0 This result was disappointing, although not surprising. It's important for PWP because, conceptually, solanezumab (a monoclonal antibody) works the same way that the anti A-Syn vaccines work. It just targets a different protein, Amyloid. There are probably a lot of reasons why the drug failed (tau may be the appropriate target, not amyloid; the patients may have been too far progressed, etc). However, we need to keep in mind that when we see early trial results from Prothena, AffiRis and Proclara that show reduction of A-syn. You still have to prove that reducing cerebral fluid levels of the protein will actually lead to improvement in symptoms and slowing or stopping the progression. We still have a long way to go. |
||
Reply With Quote |
11-23-2016, 03:24 PM | #6 | ||
|
|||
Member
|
Quote:
|
||
Reply With Quote |
11-23-2016, 03:48 PM | #7 | ||
|
|||
Member
|
Quote:
I'm in no way trying to put a damper on this type of research. I still believe that currently, it's our best hope (even more than Nilotinib). I just wanted to remind everyone that lowering a-syn levels, as it appears the three companies we are following can do, does not mean they will slow or stop PD progression. That still needs to be proven. Last edited by Tupelo3; 11-23-2016 at 08:30 PM. |
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Can Alpha Synuclein be seen using a microscope? | Parkinson's Disease | |||
Too much or too little alpha-synuclein | Parkinson's Disease | |||
Alpha-synuclein | Parkinson's Disease | |||
Alpha synuclein | Parkinson's Disease | |||
Alpha synuclein news | Parkinson's Disease |